1.
|
Phase: Phase IV
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GERCOR-TAUROX, SANOFI-GERCOR-TAUROX, EU-20573, NCT00274885
|
|
2.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: CAP001, PDDG/CAP001, NCT00854477
|
|
3.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: FRE-FNCLCC-ACCORD-11/0402, EU-20512, NCT00112658
|
|
4.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGI-RUB-048, NCT00113256
|
|
5.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 79
Sponsor: Pharmaceutical / Industry
Protocol IDs: AMT/P2CA/001, LC003AURON2005, NCT00332280
|
|
6.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 20 to 85
Sponsor: Other
Protocol IDs: AMC0183, NCT00689715
|
|
7.
|
Phase: Phase III, Phase II
Type: Supportive care
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: NNR-02, NCT00753441
|
|
8.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CONKO 004, CCT-NAPN-16752, NCT00785421
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GV-001.004, NCT00051467
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: CRUK-TELOVAC-V4, EUDRACT-2006-000461-10, EU-20683, ISRTCN43482138, NCT00425360, TELOVAC
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC6596, EUDRACT: 2006-003086-14, NCT00417209
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181114, NCT00428220
|
|
13.
|
Phase: Phase III
Type: Health services research
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SWS-SAKK-95/06, SAKK-95/06, EU-20711, SWS-SAKK-E-MOSAIC, NCT00477919
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: RC-57 crossover, NCT00440167
|
|
15.
|
Phase: Phase III
Type: Supportive care
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 06.23.CLI, NCT00455247
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: TASMC-07-NA-132-CTIL, NCT00486460
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 01023017, NCT00498225
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IPC-BAYPAN, BAYPAN, INCA-RECF0426, IPC-2005-006, NCT00541021
|
|
19.
|
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2005-0901, NCT00513357
|
|
20.
|
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: INSYS-INS-05-001, INS-05-001, NCT00538850, NCT00538850
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC10547, AVE0005, EudraCT 2007-003476-19, NCT00574275
|
|
22.
|
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: INSYS-INS-06-007, INS-06-007, NCT00538863
|
|
23.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GERCOR-LAP-07-D07-1, GERCOR-LAP-07-D07-1, EU=20827, ROCHE-GERCOR-LAP-07-D07-1, EudraCT- 2007-001174-81, NCT00634725
|
|
24.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 to 80
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GERCOR-PAM07-D07-2, GERCOR-PAM07-D07-2, EUDRACT 2007-002115-59, EU-20837, PFIZER-GERCOR-PAM07-D07-2, NCT00662688
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 20 to 85
Sponsor: Other
Protocol IDs: H-0509-513-157, NCT00679913
|
